Search results
577 Results for 'Medicine'
- Technologies (64)
- Collaborations (3)
- Team (0)
- News (404)
- Pages (0)
- Multimedia (106)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 64
-
Injectable Hydrogel Adhesive for Improved Muscle Regeneration
A super-strong, stretchy, and self-healing biomaterial that adheres to muscles and helps them heal faster after injury. -
Ropirio: Novel Treatments Targeting the Lymphatic System
Ropirio is commercializing the world’s first drug that directly targets and reactivates lymph vessels, a portfolio of other lymph-targeting small molecules, and a preclinical platform for discovering more. -
Metabolically Labeled CAR-T Cells Against Cancer
Through a simple and effective metabolic labeling approach, patient-derived T cells engineered to carry immune-enhancing cytokines on their surfaces could help expand adoptive T cell therapies to treatment of solid tumors and improve blood cancer therapies. -
Engineered Live Biotherapeutic Product (eLBP) to Protect the Microbiome from Antibiotics
eLBP is a safe and cost-effective therapeutic for patients treated with beta-lactam antibiotics that safeguards against the loss of health-essential microbes while preventing the development and spread of antibiotic resistance. -
ReConstruct: Vascularized tissue for breast reconstruction and augmentation
ReConstruct is a platform for growing, vascularizing, and implanting patient-derived tissues that enable safer breast reconstruction after cancer surgery. -
Immunostimulatory RNA Therapeutic for Treatment of Cancer and Infectious Disease
Our novel dsRNAs stimulate the immune system to inhibit cancer, bacterial, and viral infections including SARS-CoV-2 and multiple influenza strains.
Collaborations 3
-
Brigham-Wyss DxA
The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests. -
Biomarker Discovery Laboratory (BDL)
Bridging the diagnostic gap from biomarker discovery to market-ready test kits and instruments through cutting-edge technology development and clinical collaboration. -
Wyss Brain Targeting Program
Advancing brain delivery approaches that enable more safe and effective brain-targeted therapeutics.
News 404
Multimedia 106
-
Video/Animation20ish Questions with Elliot Chaikof20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows Elliot Chaikof, an Associate Faculty member at the Wyss Institute as well as the Chair of the Department of Surgery & Surgeon-in-Chief at Beth Israel Deaconess Medical Center.... -
Video/AnimationEnhancing Lactation to Improve Infant and Maternal HealthLactation Biologics is developing a long-lasting, self-injectable treatment to help nursing mothers feed their babies naturally, helping them get the best nutrition possible in the face of climate disasters and supply chain disruptions. Credit: Wyss Institute at Harvard University -
Video/AnimationReConstruct – 3D Bioprinted Vascularized Fat Tissues for Breast ReconstructionBreast cancer affects 15% of all women. Current options for breast reconstruction are insufficient and have poor patient outcomes. A research team at the Wyss Institute is addressing this clinical need by fabricating vascularized adipose tissue flaps for therapeutic use. Credit: Wyss Institute at Harvard University -
Video/AnimationReimagine the World – Volume 2 – Diagnostics AcceleratorTwo clinicians collaborating with the Wyss Diagnostics Accelerator (DxA), Lise Johnson and Craig Hersh, as well as two members of the Wyss DxA Industrial Partnership Program, Nell Meosky Luo and Andy Levin, share how they would Reimagine the World and the personal stories that fuel their passion for the work they are doing. Credit: Wyss... -
Video/AnimationFeCILL: Reimagining How We Treat the Sickest PatientsOpportunistic fungal infections usually only affect patients whose immune systems are compromised, but when they do, they are often deadly – the mortality rate for these infections can be as high as 25%. Existing antifungal treatments have high levels of toxicity, and can harm the patient more than they help. Researchers at the Wyss Institute... -
Video/AnimationMetabolic T cell Labeling: simple and effective enhancement of therapeutic T cells with immune-stimulating cytokinesThis animation shows how the surface of patient-derived T cells is metabolically labeled with azido-sugar molecules that then can be used to attach immune-enhancing cytokines with the help of click chemistry. The approach could help expand adoptive T cell therapies to treatment of solid tumors. Credit: Wyss Institute at Harvard University